High expression of GSKIP is associated with poor prognosis in meningioma. Issue 50 (16th December 2022)

• Record Type: Journal Article
• Authors: Cheng, Yu-Wen; Chen, Yang-Yi; Lin, Chien-Ju; Lieu, Ann-Shung; Tsai, Hung-Pei; Kwan, Aij-Lie
• Is Part Of: Medicine. Volume 101:Issue 50(2022)
• Page Start: e32209
• Publication Date: 2022-12-16
• Subjects: GSK3β interaction protein -- meningioma -- prognosis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000032209
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Meningiomas are the most common extra-axial primary central nervous system tumors. There is no effective treatment or targeted therapy for meningioma except excision and radiotherapy. glycogen synthesis kinase 3β interaction protein (GSKIP) is an A-kinase anchor protein that has cytosolic scaffolding function and binds to a protein kinase A and glycogen synthesis kinase 3β to modulate different biological processes and malignant tumorigenesis through the Wnt pathway. The purpose of this study was to investigate the relationship between GSKIP expression and the clinico-pathological parameters in meningioma using immunohistochemical staining. We collected samples from 74 patients, from 2008 to 2012, in the Kaohsiung Medical University Hospital that had data on the staging and prognosis of the meningioma pathological section. Chi-square, Kaplan-Meier method, and cox regression were used to analyze the correlation between clinical parameters and immunohistochemistry staining for GSKIP. Following our immunohistochemical score, we found that higher expression of GSKIP was associated with high World Health Organization grading, recurrence, malignant transformation, and reduced overall survival time and recurrence-free survival time in meningioma. GSKIP may be a biomarker of poor prognosis and a target protein for therapy in meningioma.